- Muscle quality and age: cross-sectional and longitudinal comparisonsE J Metter
The National Institute on Aging, Gerontology Research Center, Baltimore, Maryland 21224 6823, USA
J Gerontol A Biol Sci Med Sci 54:B207-18. 1999..In addition, CREAT may measure a muscle property not accounted for by CSA or FFM...
- Neuroprotective agents for clinical trials in ALS: a systematic assessmentB J Traynor
Neurology Clinical Trials Unit, Department of Neurology, Massachusetts General Hospital, Boston, USA
Neurology 67:20-7. 2006..Riluzole is currently the only Food and Drug Administration-approved treatment for ALS, but its effect on survival is modest...
- A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALSPaul H Gordon
Department of Neurology, Columbia University, New York, USA
Amyotroph Lateral Scler 9:212-22. 2008..This phase II design was efficient, leading to treatment selection after just 60 patients, and can be used in other phase II trials to assess different agents...